Yuichi Shinozaki
Takatsuki, 5691125, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Glucose transporter 9 inhibition as a potential novel approach for lowering uric acid.
Journal: European journal of pharmacology
Published: January 28, 2026
Effects of salt supplementation in uninephrectomized KK-Ay mice: Examining the potential of a diabetic kidney disease model.
Journal: The Journal of toxicological sciences
Published: November 01, 2023
Establishment of a new nonalcoholic steatohepatitis model; Ovariectomy exacerbates nonalcoholic steatohepatitis-like pathology in diabetic rats.
Journal: Journal of pharmacological and toxicological methods
Published: February 22, 2022
Effects of excessive sodium chloride loading in the spontaneously diabetic torii (SDT) fatty rats, a preclinical model of type 2 diabetes mellitus.
Journal: The Journal of toxicological sciences
Published: December 02, 2021
Salt loading with unilateral nephrectomy accelerates decline in glomerular filtration rate in the hypertensive, obese, type 2 diabetic SDT fatty rat model of diabetic kidney disease.
Journal: Clinical and experimental pharmacology & physiology
Published: October 04, 2021
JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat.
Journal: European journal of pharmacology
Published: September 25, 2020
Sodium-glucose cotransporters: Functional properties and pharmaceutical potential.
Journal: Journal of diabetes investigation
Published: January 03, 2020
JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors.
Journal: American journal of physiology. Renal physiology
Published: October 22, 2019
JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
Journal: European journal of pharmacology
Published: May 21, 2019
A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents.
Journal: Experimental dermatology
Published: April 13, 2017
Improvement of spontaneous locomotor activity with JAK inhibition by JTE-052 in rat adjuvant-induced arthritis.
Journal: BMC musculoskeletal disorders
Published: March 05, 2015
Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo.
Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]
Published: February 07, 2014
Last Updated: 09/26/2026